MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics

“Cold-chain logistics remain one of the most significant barriers to scaling access to allogeneic cell therapies.”

Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics

“In our randomized Phase 2 trial in acute lung injury, we have already delivered agenT-797 to mechanically ventilated patients within days of regulatory authorization, even in an active conflict zone.”

Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics

“Removing the cold chain could take that deployability to a new level: a living immune therapy stocked like a conventional drug and administered wherever critically ill patients present, including remote, resource-limited, and austere settings.”

Nils Rudqvist, Ph.D., Senior Director, Research at MiNK Therapeutics

“iNKT cells are a rigorous benchmark for stabilization because their value lies in rapid, coordinated function: they activate within hours and orchestrate both innate and adaptive immunity, so any approach must preserve that full functional program, not just viability.”

Nils Rudqvist, Ph.D., Senior Director, Research at MiNK Therapeutics

“And because iNKT cells do not require human leukocyte antigen (HLA) matching, one manufacturing run can supply many patients.”

Nils Rudqvist, Ph.D., Senior Director, Research at MiNK Therapeutics

“Pairing that scalability with room-temperature stability could take cell therapy beyond the specialized centers equipped for cryopreserved products and bring it to community hospitals and patients worldwide.”